Phase 3 data show subcutaneous teprotumumab significantly reduces proptosis in adults with active thyroid eye disease compared with placebo. Topline data were announced from a phase 3 trial evaluating ...
The Redback IFV (pictured above) weighs 42 tonnes and has a length, a width, and a height of 7.9 m, 3.64 m, and 3.75 m respectively. It has a maximum on-road speed of 65 km/h with a seating capacity ...
Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. In this phase 3, double-blind, randomized, ...
Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement ...
Selinexor added to ruxolitinib increased week-24 SVR35 rates versus ruxolitinib plus placebo, meeting a co-primary endpoint and reinforcing SVR35 as a clinically meaningful efficacy benchmark.
Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...
The biggest stories of the day delivered to your inbox.
A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...
Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.
Google has launched the Android Auto 16.3 update in the beta track. While there are no major user-facing changes, this version reportedly includes hints of video apps and the light theme. Google has ...